Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Leprosy, also called Hansen disease or Hansen's disease, is described in the packet as a chronic infectious disease affecting primarily the skin and peripheral nervous system. Synonyms in the packet also reference Mycobacterium leprae as the causative organism. The packet lists several subtypes: lepromatous, tuberculoid, paucibacillary, borderline, indeterminate and multibacillary leprosy. Prevalence is recorded as unknown in this packet, so no frequency estimate is given here.
The packet's synonym list describes the condition as a Mycobacterium leprae infectious disease. No genes are listed for this condition in the packet, and no inheritance pattern is recorded. Further detail on transmission or host factors is not certified in this packet.
Diagnostic methods and criteria are not certified in this packet. Among the listed research records, one trial from the University of Brasilia (NCT07515989) evaluates the accuracy of polymerase chain reaction on ultrasound-guided ulnar perineural subcutaneous aspirate for the diagnosis of leprosy and for assessing cure.
Established treatment coverage is not certified in this packet, and no FDA-approved therapies are recorded. The packet lists dovramilast (sponsor: Medicines Development for Global Health) with an orphan drug status of DESIGNATED for treatment of leprosy (Hansen disease). An orphan designation is not an approval and does not by itself indicate the stage of development.
13 trials found
Natural history and prognosis are not certified in this packet.
The packet records nine active clinical trial entries for leprosy on ClinicalTrials.gov, with sponsors that are mainly academic. Examples include NCT05597280, a Phase 3 study of bedaquiline-enhanced post-exposure prophylaxis sponsored by the Institute of Tropical Medicine, Belgium (recruiting; started 2023-03-22, estimated completion 2027-03-15), and NCT05243654, a Phase 2 study of adjunct metformin for multibacillary leprosy sponsored by Oxford University Clinical Research Unit Indonesia (recruiting; started 2022-10-01, estimated completion 2026-09-30). NCT06222372, sponsored by Annemieke Geluk, is titled Novel Interventions and Diagnostic Tests for Leprosy (recruiting; started 2020-03-04). Other entries address diagnostic accuracy (NCT07515989), early detection of skin-related neglected tropical diseases in sub-Saharan Africa (NCT07506967), mental health integration in Ghana (NCT07248462), epidemiological characteristics in Costa Rica (NCT07448389) and Rab 32 gene polymorphisms as a prognostic factor (NCT06819449). The full list is available through the ClinicalTrials.gov search for leprosy.
Data assembled from 5 of 12 sources · Last updated Nov 17, 2026, 8:27 PM UTC
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
European rare disease database
Genetic and Rare Diseases Info Center
AI-curated news mentioning leprosy
Updated Aug 30, 2026
A study published on PubMed examines the clinical profile of uveitis in leprosy patients in Egypt, providing insights into the ocular complications associated with the disease. This research contributes to the understanding of leprosy-related conditions and their management.
A retrospective analysis of 54 cases reveals key clinicopathological features of lupus erythematosus panniculitis. This study enhances understanding of LEP, potentially guiding future research and treatment strategies.
A case report details lepromatous leprosy in a non-endemic setting, highlighting chronic painless ulcers and inflammatory arthropathy. This study contributes to understanding the disease's presentation outside typical regions.
A study shows that monthly rifampin-moxifloxacin-minocycline therapy significantly reduces type 1 reactions in patients with Hansen disease. Conducted on 111 patients, the research highlights the potential of this therapy as an alternative to the standard multidrug therapy.